G6PD and Plasmodium vivax malaria: To put this in context, however, the additional US$39 million provider expenses required for global G6PD screening and treatment represents only 1% of the US$3.1 billion spent on malaria control activities in 2017, an investment that could potentially halve the global burden of P. vivax. Since a large proportion of vivax malaria episodes are attributable to relapses [43,44], investment in safe and effective radical cure will be crucial to achieving the timely elimination of vivax malaria.